Lilly obesity pill uptake

- Eli Lilly's newly launched obesity pill Foundayo recorded a modest second week with nearly 4,000 prescriptions, lagging Novo Nordisk's Wegovy in early uptake. - Reports from Reuters, Bloomberg and Seeking Alpha flagged the 3,900–4,000 prescription second‑week figure, and Lilly refused to list Mounjaro on Australia's PBS over a pricing disagreement. - Early prescription velocity suggests adoption is tentative and will depend on reimbursement, substitution, and sustained demand. (reuters.com) (afr.com)